Aspira Women's Health Inc. reported a net loss of $1.4 million for the nine months ended September 30, 2026, a significant improvement from the $9.4 million loss in the prior year, primarily driven by a $4.5 million gain from the change in fair value of warrant liabilities. Total revenue decreased to $5.9 million from $7.0 million year-over-year, while total operating expenses were reduced from $11.1 million to $8.5 million.
Aspira Women's Health announced that its previously issued financial statements for the first two quarters of 2026 should no longer be relied upon due to material errors in the Statement of Cash Flows. The errors involved the misclassification of loan proceeds and repayments as operating activities instead of financing activities. The company plans to restate these periods, though the adjustments have no impact on the reported balance sheets, statements of operations, or total net change in cash.